| [1] |
Kay R, Takei F, Humphries RK. Expression cloning of a cDNA encoding M1/69-J11d heat-stable antigens[J]. J Immunol, 1990, 14 5(6):1952-9.
|
| [2] |
Henniker AJ. CD24[J]. J Biol Regul Homeost Agents, 2001, 15 (2):182-4.
|
| [3] |
Kay R, Rosten PM, Humphries RK. CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor[J]. J Immunol, 1991, 147(4):1412-6.
|
| [4] |
Buck K, Hug S, Seibold P, et al. CD24 polymorphisms in breast cancer: impact on prognosis and risk[J]. Breast Cancer Res Treat, 20 13, 137(3):927-37.
|
| [5] |
Leary A, Pautier P, Tazi Y, et al. The molecular biology of epithelial ovarian cancer[J]. Bull Cancer, 2012, 99(12):1161-73.
|
| [6] |
Das PM, Bast RC, Jr. Early detection of ovarian cancer[J]. Biomark Med, 2008, 2(3):291-303.
|
| [7] |
Reyes-Reyes EM, Akiyama SK. Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells[J]. Exp Cell Res, 2008, 314(11-12):2212-23.
|
| [8] |
Sagiv E, Arber N. The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy[J]. Expert Rev Gastroenterol Hepatol, 2008, 2(1):125-33.
|
| [9] |
Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule[J]. J Mol Histol, 2004, 35 (3):255-62.
|
| [10] |
Kristiansen G, Denkert C, Schlüns K, et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival[J]. Am J Pathol, 2002, 161(4):1215-21.
|
| [11] |
Bretz NP, Salnikov AV, Perne C, et al. CD24 controls Src/ STAT3 activity in human tumors[J]. Cell Mol Life Sci, 2012, 69 (22):3863-79.
|
| [12] |
Bapat SA, Mali AM, Koppikar CB, et al. Stem and progenitorlike cells contribute to the aggressive behavior of human epithelial ovarian cancer[J]. Cancer Res, 2005, 65(8):3025-9.
|
| [13] |
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance[J]. Nat Rev Cancer, 2005, 5(4):275-84.
|
| [14] |
Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality?[J]. Nat Med, 2009, 15(9):1010-2.
|
| [15] |
Gao MQ, Choi YP, Kang S, et al. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells[J]. Oncogene, 2010, 29(18):2672-80.
|
| [16] |
Kang KS, Choi YP, Gao MQ, et al. CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype[J]. Biochem Biophys Res Commun, 2013, 432(2):333-8.
|
| [17] |
Miller E, Shapira S, Gur E, et al. Increased expression of CD24 in nonmelanoma skin cancer[J]. Int J Biol Markers, 2012, 27(4): e331-6.
|
| [18] |
Pinato DJ, Nya P, Sharma R, et al. CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma[J]. J Clin Pathol, 2013, 66(3):256-9.
|
| [19] |
Bauerschlag D, Brautigam K, Moll R, et al. Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary[J]. J Cancer Res Clin Oncol, 20 13, 139(2):347-55.
|
| [20] |
Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy[J]. Int J Cancer, 2004, 11 2(1):14-25.
|
| [21] |
Choi YL, Kim SH, Shin YK, et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors[J]. Gynecol Oncol, 20 05, 97(2):379-86.
|
| [22] |
Wei X, Dombkowski D, Meirelles K, et al. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics[J]. Proc Natl Acad Sci U S A, 2010, 107(44):18874-9.
|
| [23] |
Kristiansen G, Machado E, Bretz N, et al. Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis[J]. Lab Invest, 2010, 90(7):1102-16.
|
| [24] |
Sagiv E, Starr A, Rozovski U, et al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA[J]. Cancer Res, 2008, 68(8):2803-12.
|
| [25] |
Salnikov AV, Bretz NP, Perne C, et al. Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas[J]. Br J Cancer, 2013, 108(7):1449-59.
|
| [26] |
Koh J, Lee SB, Park H, et al. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells[J]. Biochem Biophys Res Commun, 2012, 427(2):373-8.
|
| [27] |
Su D, Deng H, Zhao X, et al. Targeting CD24 for treatment of ovarian cancer by short hairpin RNA[J]. Cytotherapy, 2009, 11 (5):642-52.
|
| [28] |
Mori I, Yang Q, Kakudo K. Predictive and prognostic markers for invasive breast cancer[J]. Pathol Int, 2002, 52(3):186-94.
|
| [29] |
Kim K, Min HS, Chie EK, et al. CD24 expression predicts distant metastasis in extrahepatic bile duct cancer[J]. World J Gastroenterol, 2013, 19(9):1438-43.
|
| [30] |
Tang J, Cai H, Lin L, et al. Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma[J]. Clin Transl Oncol, 2013, 15(7):541-7.
|
| [31] |
Kristiansen G, Schlüns K, Yongwei Y, et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients[J]. Br J Cancer, 2003, 88(2):231-6.
|
| [32] |
Surowiak P, Materna V, Kaplenko I, et al. Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue[J]. Int J Gynecol Cancer,2006,16(2):515-21.
|
下载:
